The global shingles vaccine market, valued at USD 4.86 billion in 2024, is projected to more than double to USD 12.31 billion by 2032, expanding at a robust CAGR of 12.35% from 2025 to 2032. This growth is fueled by the increasing incidence of shingles among the aging population, widespread integration of shingles vaccines into national immunization programs, and significant product innovation from leading pharmaceutical companies.
Shingles, a viral infection caused by the reactivation of the varicella-zoster virus, is known for its painful rash and complications such as postherpetic neuralgia. With the growing elderly population—those most vulnerable to shingles—governments and healthcare providers worldwide are ramping up preventive strategies through vaccination campaigns.
Get Insights into Market Movements: Request a Sample Report! https://www.snsinsider.com/sample-request/7051
Market Dynamics and Growth Drivers
The rising global incidence of shingles, especially among individuals aged 50 and above, is a primary factor driving demand for effective vaccination. Increasing awareness about the long-term complications of the disease has led to strong public and private sector support for immunization efforts. Moreover, advancements in recombinant vaccine technology, such as GlaxoSmithKline’s (GSK) Shingrix, have significantly improved the safety and efficacy profile of shingles vaccines, further accelerating uptake.
Economic development in emerging markets has enhanced healthcare access, while public-private partnerships have contributed to better distribution infrastructure. Governments worldwide are actively integrating shingles vaccines into their national immunization schedules, backed by favorable reimbursement policies, particularly in developed regions.
Additionally, ongoing clinical research and development activities are fostering innovation. GSK’s recent announcement in April 2024 highlighted that its long-term ZOSTER-049 study showed over 10 years of protection against shingles in adults aged 50 and above with Shingrix. In June 2024, Dynavax initiated Phase 1/2 trials for a new shingles vaccine candidate, underscoring the dynamic R&D landscape.
Regional Market Highlights
North America: Market Leadership and Innovation Hub
North America continues to lead the global shingles vaccine market, commanding approximately 61% of the market share in 2024. The United States dominates the regional market, accounting for an impressive 83% share within North America. The region’s growth is underpinned by its strong preventative healthcare focus, a well-established healthcare infrastructure, and proactive government support.
Inclusion of shingles vaccines in the National Immunization Program, along with broad insurance coverage and extensive public awareness campaigns, has resulted in high vaccination rates. Major pharmaceutical players headquartered in the U.S., such as GSK and Merck, are leveraging robust R&D and distribution networks to maintain a competitive edge. The fast adoption of recombinant vaccines like Shingrix has further contributed to the region’s dominance.
Europe: Policy Support and High Vaccine Penetration
Europe remains a lucrative region in the shingles vaccine market, backed by improved public understanding of immunization, favorable government policies, and easy access to vaccines. Countries like Germany, the UK, and France have adopted shingles vaccines in their national immunization strategies, which has significantly improved vaccine coverage.
Germany, in particular, stands out due to its aging population and well-developed healthcare system. Government-sponsored immunization drives and the widespread availability of Shingrix have boosted market penetration. Moreover, the European Union’s strong manufacturing capacity is highlighted by its USD 29.2 billion export value in vaccines for human use in 2023, supporting both regional and global supply.
Navigate Business Success with Essential Insights Get Avail Enquiry on Report! https://www.snsinsider.com/enquiry/7051
Asia Pacific: Fastest-Growing Region
With a forecasted CAGR of 13.33% between 2025 and 2032, Asia Pacific is poised to be the fastest-expanding shingles vaccine market. Key drivers include a rapidly aging population, rising disposable incomes, and substantial improvements in healthcare infrastructure across developing economies.
Countries such as China, India, and Japan are showing considerable growth due to high unmet medical needs and increasing health awareness. Japan, in particular, has witnessed a significant increase in shingles vaccine uptake driven by its aging demographic and government efforts to include shingles vaccinations in public health programs. Continuous regulatory approvals and awareness campaigns are helping transform Asia Pacific from a developing market into a major global player.
LAMEA: Gradual but Promising Growth
The Latin America, Middle East, and Africa (LAMEA) region accounts for a smaller share of the global shingles vaccine market but is witnessing steady growth. Increasing government interest in preventive healthcare, growing public awareness about shingles, and efforts to improve vaccine availability are contributing to this positive trend.
However, challenges such as lower income levels, limited healthcare infrastructure, and uneven awareness across the region may hinder rapid market growth. Nonetheless, with increasing investment and international collaboration, the region offers long-term potential.
Leading Industry Players
Prominent companies operating in the shingles vaccine space include:
- GlaxoSmithKline (GSK)
- Merck & Co., Inc.
- Pfizer Inc.
- SK bioscience
- GeneOne Life Science
- BioNTech SE
- Vaccitech
- Jiangsu Recbio Technology Co., Ltd.
- Changchun BCHT Biotechnology Co.
- Curevo Inc.
These companies are focused on vaccine innovation, clinical development, and expanding access across emerging markets.
Recent Developments
- April 2024: GSK announced long-term efficacy results from the ZOSTER-049 study, confirming Shingrix provides over a decade of protection against shingles in adults over 50.
- June 2024: Dynavax initiated Phase 1/2 trials for its next-generation shingles vaccine, signaling growing competition and innovation in the market.
Seize Business Opportunities with Key Insights Get Avail Checkout on Report! https://www.snsinsider.com/checkout/7051
Key Market Segments
The shingles vaccine market is segmented by product, vaccine type, and region:
- By Product: Shingrix, SKYZoster, Zostavax
- By Vaccine Type: Live Attenuated Vaccine, Recombinant Vaccine
- By Region:
- North America: U.S., Canada, Mexico
- Europe: Germany, UK, France, Italy, Spain, Poland, Turkey, Rest of Europe
- Asia Pacific: China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of MEA
- Latin America: Brazil, Argentina, Rest of Latin America
As the global population continues to age and governments increasingly prioritize preventive health strategies, the shingles vaccine market is well-positioned for sustained growth. With strong regional dynamics, innovative product pipelines, and expanding global access, industry stakeholders can expect a promising outlook through 2032 and beyond.
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave – Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Mail us: [email protected]
